Skip to main content
Skip to content
Case File
efta-efta01479583DOJ Data Set 10Correspondence

EFTA Document EFTA01479583

Date
Unknown
Source
DOJ Data Set 10
Reference
efta-efta01479583
Pages
0
Persons
0
Integrity
Loading PDF viewer...

Summary

Ask AI About This Document

0Share
PostReddit

Extracted Text (OCR)

EFTA Disclosure
Text extracted via OCR from the original document. May contain errors from the scanning process.
Subject: Re: Biotech Update... [C] From: Tazia Smith ‹ > Date: Thu, 08 May 2014 14:23:51 -0400 To: [email protected] Cc: Nav Gupta Paul Morris Vahe Stepanian Vinit Sahni Classification: Confidential Jeffrey - Updating you on your biotech basket because most of the names are struggling to rebound from the recent rotational sell-off, exception is GILD which has good valuation support, showed a strong earnings beat, and is back up to —$79.36 (your avg cost is $79.41). FMI reported earnings after the close yesterday, which were inline but guidance was on the low end. Stock has sold off 15% (down to —$24 currently from from a high of $30 yesterday). Please find your updated P/L below. Included SGMO chart - that company reported a moderately better quarter on Tuesday evening, hence the 3% uptick and several positive reports from the competitors across the Street. Source: Bloomberg and Pershing LLC as of 5/8/14 From: Tazia Smit To: [email protected], Cc: Nav Gupta , Pau Morris, , Vahe , Vinit Sahni Date: 04/22/2014 04:16 PM Subject: Re: Biotech Update... i ea eat, s ares halted [C] Classification: Confidential Jeffrey - sure you see this, just making sure, Gilead shares are halted in the after-market following a significant top and bottom-line earnings beat ($1.48 vs $0.92 cons eps, $5bn on the topline vs. expecations of $3.96bn) as EFTA01479583 you know, you're long 8100 shares at an average price of $79.41, stock closed today at $72.86, just reported. Shares expected to re-open at 4:30pm From: Taz' Stepanian Biotech Update... [C] Classification: Confidential Jeffrey - jeevacation mail.com Cc: Paul Morris, Vahe Nav Gupta Vinit Sahni Da e: :42 PM Subj Biotech forming a base to some extent (strong market backdrop, clearly) you're up $906k on your basket excluding the Ariad (outlier due to M&A prospects vs. group drivers) 1-mo price history charts below. SGMO lmo Price History BIIB lmo Price History GILD lmo Price History FMI lmo Price History EFTA01479584 Tazia Smith Director I Key Client Partners - US DB Securities Inc Deutsche Asset & Wealth Management 345 Park Avenue, 10154-0004 New York, NY, USA Tel. Fax Mobile Email EFTA01479585

Technical Artifacts (1)

View in Artifacts Browser

Email addresses, URLs, phone numbers, and other technical indicators extracted from this document.

Forum Discussions

This document was digitized, indexed, and cross-referenced with 1,400+ persons in the Epstein files. 100% free, ad-free, and independent.

Annotations powered by Hypothesis. Select any text on this page to annotate or highlight it.